Leadership

Alan Au

Managing Partner

Alan is a veteran in healthcare related investments. He is Founder/Managing Partner at GT Healthcare Partners, an innovative private equity operator focusing on cross border healthcare investments. Alan was senior adviser to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE:SCR, privatized in Dec 2013, when Alan was Chairman of the Special Committee on the Board of Directors). He was also a member of the Board, Audit Committee and Compensation Committee of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in Sep 2016) from 2013 to 2016. Separately, Alan is a member of the Board, Audit Committee and Chairman of Nomination Committee of Cellular BioMedicine Group Inc. (Nasdaq: CBMG), a leader in immune-oncology in China. In addition, he has served as a panel member for the Entrepreneur Support Scheme (ESS Program) of the Innovation and Technology Fund of the Hong Kong SAR Government since 2014. Before that, Alan was Head of Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&A in the region between 2011 and 2012. Prior to that, he was Executive Director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2010, and Investment Director at Morningside Group, managing healthcare investments in Asia from 2000 to 2005. From 1995 to 1999, Mr. Au worked at KPMG and KPMG Corporate Finance Ltd., taking care of regional M&A transactions and financial advisory services. Alan is a Certified Public Accountant in the U.S. and holds the Chartered Financial Analyst (CFA) designation. He is an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants. Alan received his Bachelor’s degree in Psychology from the Chinese University of Hong Kong, and a Master’s degree in Management from Columbia Business School in New York.

MingXi Li, Ph.D.

Partner

Dr. MingXi Li serves as Partner at GT Healthcare Capital Partners. Experienced with identifying innovative technologies and commercializing them, MingXi is a US trained professional focusing on life science sector with keen understanding of global and China healthcare market. He has established a track record of investing in China as well as cross-border transactions, and stayed well connected with industrial leaders, entrepreneurs, investors and academia in both China and US. MingXi serves on the board of a number of prominent pharmaceutical and diagnostic companies in China as well. He was Senior Director at Simcere Pharmaceutical Group from 2013 to 2017, and managed Simcere’s portfolio of investments (>150M USD) in various venture funds, including Cormorant Asset Management (MA, USA), Ally Bridge Group (HK), Partners Innovation Fund (MA, USA), PointGuard Ventures (CA, USA), Bohe Angels (Suzhou, China) and Tenyall Capital (Nanjing, China). He also served on the investment committee of Tenyall Capital. MingXi graduated with a B.S. in Biological Science and Biotechnology from Tsinghua University and has a Ph.D. in Biochemistry from University of Illinois at Urbana-Champaign. Earlier in his career, he worked in Jiuding Capital, covering Chinese pharma/IVD/hospital sectors, and later at Simcere Pharma/Bioscikin covering clinical and pre-clinical stage biopharma investments globally.

Jason Yeung

Partner

Senior financial industry expert, leading a professional team of top financial institutions in Europe and the United States for more than 20 years.I have rich experience and profound understanding of asset allocation, investment analysis, venture capital, mergers and acquisitions, securities issuance, underwriting, trading and other fields, and have deep connections in the financial and investment circles.Since the 1990s, Mr. Young has been working in top investment Banks such as jpmorgan chase, Goldman sachs, citigroup, bank of America merrill lynch and credit suisse. He is the first generation of local investment bankers in Hong Kong.Senior team, Mr Yang has led to its private bank clients, to offer more than $two billion in asset allocation suggest, with a stable and excellent performance, earning the trust of many wealthy family and institutional clients, also was in charge of securities issuance and underwriting business, successfully assist inter-city railway, CLP power Hong Kong and Taiwan Chinese steel enterprises going public.Mr. Yang is a member of the 11th henan provincial committee of the Chinese people's political consultative conference.Mr. Yeung graduated from the department of business administration of the Chinese university of Hong Kong with a bachelor's degree.

Jason Yeung is a Partner at GT Healthcare Capital Partners. Jason has over 20 years of investment experience, most recently as a Managing Director at Credit Suisse’s Hong Kong office, where Jason led a professional team of seven to serve ultra-high net worth family offices, institutions and major corporations. At Credit Suisse, Jason worked closely with investment banking division to advise and refer capital market transactions, IPOs, block trades, placements, M&A advisory, as well as leveraged financing transactions for clients. Prior to Credit Suisse, Jason was Managing Director, Investments at Merrill Lynch (Asia Pacific), whose seven-person professional team was one of the top advisor teams with highest client assets under management and revenue. Before joining Merrill Lynch, Jason was Managing Director of Megawealth Division at Citigroup Private Bank, where he advised ultra-high net worth clients in equity, fixed income, derivatives, private equity and other alternative investments. Jason also worked at Goldman Sachs (Executive Director, Head of Institutional US & International Equity Sales) and JPMorgan (Associate, Equity Capital Market). He began his career as a Management Associate, Commercial Banking at Citibank. Jason received a Bachelor’s degree in finance from the Chinese University of Hong Kong and a Certified Investment Management Analyst certification from the Wharton Business School at The University of Pennsylvania.

Professor Lo Yuk Lam

Chairman

Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service. He is an Independent Non-Executive Director at Luye Pharma Group Ltd. (HKEX: 2186.HK), Independent Non-Executive Director at CSPC Pharmaceutical Group Ltd. (HKEX: 1093.HK), and Independent Director at Sinovac Biotech Ltd. (Nasdaq: SVA). Professor Lo is currently serving as the Chairman of the Advisory Council of the Food and Health Bureau of the Hong Kong Government, an Executive Committee Member of the Chinese Manufacturers’ Association of Hong Kong (“CMA”) and Chairman of the Education Committee of CMA. He is also the Honorary Founding Chairman of Hong Kong Bio-Organization. In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology, a member of the Advisory Committee of the Vocational Training Council, Adjunct Professor of the Chinese University of Hong Kong and Honorary Professor of several universities in China. He was heavily involved in several committees of the Hong Kong Government, including the Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and the Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, Hong Kong Government. In Mainland China, Professor Lo is a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, including the prestigious “World’s Outstanding Chinese Award” in 2008 and China’s “Top Ten Financial and Intelligent Persons” in 2007.

Jingwu Zang, Ph.D.

Scientific Advisor

Dr. Jingwu Zang received his medical degree from Shanghai JiaoTong University School of Medicine and a PhD in Neuroimmunology in Belgium, where he started his illustrious pursuit of an immune-therapy for autoimmune disease (multiple sclerosis) through basic and clinical research. Dr. Zang was a post-doctoral fellow of the US National MS Society at Harvard Medical School and later joined the faculty at Baylor College of Medicine as a professor of Neurology and the research director of Multiple Sclerosis Centre in Houston. He holds an active medical license in the State of Texas in US and was the founder of Opexa Pharmaceuticals, now listed on NASDAQ. In his career after moving back to China, Dr. Zang established the Institute of Health Sciences with Chinese Academy of Sciences as the founding director and co-founded the Institute Pasteur Shanghai, a partnership institute of the Chinese Academy of Sciences and Institute Pasteur Paris. Dr. Zang published over 150 scientific papers including in Science, Nature Medicine, Nature Immunology, and book chapters in the area of immunology and received many awards for the scientific works he led in US and China. He joined GlaxoSmithKline in 2007 as SVP and founded GSK’s R&D Centre in China and later became GSK’s global head of Neurosciences Therapy Area. In 2013, Dr. Zang was appointed as CSO of Simcere pharmaceuticals and President of BioSciKin, an open drug innovation organization based in Nanjing, China. Dr. Zang founded the Third Venture Biotechnologies together with the other members of the team in 2014.

Shawn Leung, Ph.D.

Scientific Advisor

Dr. Shawn Leung is the scientific founder and CEO of SinoMab.  He has had over 20 years of experience in the biotechnology industry and is proficient in the field of therapeutic antibody development. Prior to founding SinoMab, Dr. Leung had served as the Managing Director of the Hong Kong Institute of Biotechnology, and as the Executive Director, Biology Research, of Immunomedics, Inc., of New Jersey, USA. Dr. Leung is an inventor on over 20 patents and the author of more than 70 publications (Nature, Journal of Immunology, Nucleic Acid Research, Cancer Research, Clinical Cancer Research, etc.). His works and contributions in the field of therapeutic antibodies are highly regarded in China, and he is amongst the first non-residents in China obtaining approval as the Project Leader in the 863 program for the development of novel antibody based therapy for liver cancer. Dr. Leung received his D.Phil. in Molecular Biology from Oxford University and was a Howard-Hughes Medical Research fellow at Yale University. Dr. Leung holds various adjunct positions in different academic institutions, including the Biochemistry Department of CUHK, the Third Military Medical University in Chongqing, and the Fourth Military Medical University in Xian.